Boehringer Ingelheim recently announced that its phase-two study results show that the company’s new treatment, IL-23 inhibitor risankizumab, induces remission in patients who have moderate-to-severe Crohn’s disease.
A recent study from researchers at the National Institutes of Health (NIH) shows that endocannabinoids, which are the natural chemical messengers inside the body that are similar in effect to marijuana, are important in developing habits.
Pfizer Inc. recently announced that it has granted over $1 million to finance the top breast cancer advocacy organizations that are dedicated to scientific research and quality-of-life studies concerning metastatic breast cancer (MBC).
Leaders on the U.S. House of Representatives Appropriations Committee recently approved the Fiscal Year 2017 Appropriations Act, offering $5 million in provisions to finance a research program specifically dedicated to lupus.
Health professionals and mainstream media have confirmed what the facts in medical literature have indicated for several months -- there are now superbugs that are resistant to all of the antibiotics currently available.
The Medicines Company recently completed enrollment for the second phase of its study on PCSK9si, which the company is seeking to show can reduce LDL-C, or ‘bad cholesterol,’ with just a single-dose treatment every six months.
The American Heart Association recently signed a memorandum of understanding (MOU) with the Chinese Medical Association’s Chinese Society of Cardiology, which will see the institutions cooperate on establishing measures to improve the system of care for heart attack patients in China.
Officials with the Healthcare Leadership Council recently emphasized the organization's ongoing opinion that vaccines are the most powerful and effective approach for health care intervention that is currently available to modern medicine.
Leaders at GlaxoSmithKline (GSK) and Innoviva Inc. recently announced the results of the new Salford Lung Study (SLS) in Chronic Obstructive Pulmonary Disease (COPD), which shows that using Relvar Ellipta instead of traditional treatments gives COPD patients greater relief.
Biogen recently stated that its investigational treatment for early Alzheimer’s disease (AD), aducanumab, has been accepted into the Priority Medicines (PRIME) program of the European Medicines Agency (EMA).
Astellas Pharma Inc. and Medivation Inc. recently announced that it will initiate its new phase-three clinical trial to evaluate the safety and efficacy of enzalutamide for treating patients who have triple-negative breast cancer (TNBC).
Axumin, a radioactive diagnostic agent for injections, recently received approval from the U.S. Food and Drug Administration (FDA), as the new technology may be useful in detecting recurrent prostate cancer.
Boehringer Ingelheim, a pharmaceutical company focused on research, recently announced that it seeks to improve the access that HIV and AIDS patients have to antiretroviral medication to treat their illnesses.